

FEB. 25. 2005 3:35PM

AKIMA-DTSV 28 FEB 2005
AVENTIS US PAT DEPT

NO. 2721 P. 1

PTO/88/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.TRANSMITTAL
FORM

(To be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/786,810
Filing Date	February 25, 2004
First Named Inventor	JESUS BENAVIDES et al.
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	STD1023 US CNT

4095

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> Other Enclosure(s) (please identify below): <div style="border: 1px solid black; height: 40px; width: 100%;"></div>
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.63	<input type="checkbox"/> Remarks 1. Requested for Corrected Filing Receipt (1 pg.) 2. Corrected Filing Receipt (2 pgs.)	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature	<i>Balaram Gupta</i>		
Printed name	Balaram Gupta		
Date	February 25, 2005	Reg. No.	40,009

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-746-9195 : Total No. of Pages Transmitted: 4 pgs.)

Signature	<i>Manbel Mendez</i>		
Typed or printed name	Manbel Mendez	Date	February 25, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re Application of
Jesus Benavides, et al

Examiner: Not Yet Assigned

Art Unit: 1614

Application No.: 10/786,810

Filed: February 25, 2004

Title: Composition of a CB1 Receptor Antagonist and
of a Product Which Activates Dopaminergic
Neurotransmission in the Brain, the
Pharmaceutical Compositions Comprising
Them and Their Use in the Treatment of
Parkinson's Disease

CERTIFICATE OF TRANSMISSION
 I hereby certify that this correspondence is being transmitted via
 facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
 VA 22313-1450, at (703) 746-9195, on 2-25-05
 Date of Deposit _____
 Printed Name of Person Signing Certificate Maribel Mendez
 Signature Maribel Mendez

REQUEST FOR CORRECTED FILING RECEIPT

Mail Stop
 Commissioner of Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Sir.

Attached is a copy of the "marked-up" official Filing Receipt from the Patent and Trademark Office in the above-identified application, for which issuance of a corrected filing receipt is respectfully requested.

There is an error in the Title which reads: "Combination of a CB1 receptor Antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of Parkinson's disease," and should read: "Combination of a CB1 Receptor Antagonist and of a Product Which Activates Dopaminergic Neurotransmission in the Brain, the Pharmaceutical Compositions Comprising Them and Their Use in the Treatment of Parkinson's Disease." In addition, please also note that the address of the assignee reads as "Cedex, France," which should read as "Antony, Cedex, France".

The Commissioner is hereby authorized to charge any fees, which are required by this paper to
 Deposit Account 18-1982.

Respectfully submitted,

February 25, 2005

Balaram Gupta
 Balaram Gupta, Reg. No. 40,009
 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
 Patent Department
 Route #202-206 / P.O. Box 6800
 Bridgewater, NJ 08807-0800
 Telephone (908) 231-3364
 Telefax (908) 231-2626
 Aventis Docket No. ST01023 US CNT

FEB. 25. 2005 3:36PM

AVENTIS US PAT DEPT

NO. 2721 P. 3

Page 1 of 2




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (e) DATE	ART UNIT	FIL FEE REC'D	ATTY/DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/786,810	02/25/2004	1814	1188	ST01023 US CNT		36	1

005487
 ROSS J. OEHLER
 AVENTIS PHARMACEUTICALS INC.
 ROUTE 202-208
 MAIL CODE: D303A
 BRIDGEWATER, NJ 08807

B. Gupta



CONFIRMATION NO. 3346

CORRECTED FILING RECEIPT



"OC000000013550897"

COMPUTER ENTERED

Jan 8/19/04

Date Mailed: 08/16/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jesus Benavides, Chatenay Malabry, FRANCE;
 Daniel Boccio, Fay P. Bippov, FRANCE;
 Yvette Henin, Paris, FRANCE;
 Odile Plot-Grosjean, Choisy Le Roi, FRANCE;
 Henin, Paris, FRANCE;

Assignment For Published Patent Application

Paris
 Aventis Pharma S.A., Cedex, FRANCE;

*→ Aventis Pharma S.A., Antony Cedex,
 France*

Domestic Priority data as claimed by applicant

This application is a CON of PCT/FR02/02846 08/28/2002

Foreign Applications

FRANCE 0111200 08/29/2001

If Required, Foreign Filing License Granted: 05/17/2004

Projected Publication Date: 10/21/2004

Non-Publication Request: No

Early Publication Request: No

Title

Combination of a CB1 receptor antagonist and of a product which *activates* ~~activates~~ dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).